Biosyent (Biosyent) Debt-to-Equity : 0.04 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Biosyent Debt-to-Equity?

Biosyent's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.14 Mil. Biosyent's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.77 Mil. Biosyent's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $25.91 Mil. Biosyent's debt to equity for the quarter that ended in Dec. 2023 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biosyent's Debt-to-Equity or its related term are showing as below:

BIOYF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.05 Max: 0.07
Current: 0.04

During the past 13 years, the highest Debt-to-Equity Ratio of Biosyent was 0.07. The lowest was 0.04. And the median was 0.05.

BIOYF's Debt-to-Equity is ranked better than
84.33% of 849 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs BIOYF: 0.04

Biosyent Debt-to-Equity Historical Data

The historical data trend for Biosyent's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Debt-to-Equity Chart

Biosyent Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.07

0.06

0.05

0.04

Biosyent Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.04	0.04	0.04	0.04	0.04

Competitive Comparison of Biosyent's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biosyent's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biosyent's Debt-to-Equity falls into.

Biosyent Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biosyent's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.136	+	0.774)	/	25.909
	=	0.04

Biosyent's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.136	+	0.774)	/	25.909
	=	0.04

Biosyent (OTCPK:BIOYF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biosyent Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biosyent's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosyent (Biosyent) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

RX:Canada

Address

2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1

Website

http://www.biosyent.com

Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.